When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Pfizer's ex-chair and chief executive Ian Read ... GBT acquisition after the main asset in that $5.4 billion deal – Oxbryta for sickle cell disease – was pulled from the market last month.

Pfizer Inc. discovers, develops ... and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under ...

About Pfizer Inc. and Eli Lilly and Company Pfizer Inc. discovers ... and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable ...

The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...

UBS analyst Trung Huynh maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $31.00. The company’s shares closed yesterday at $26.72. Huynh covers the ...

Meenakshi Nevatia, Managing Director of Pfizer Limited on Tuesday said that the company is planning to expand its manufacturing capacity and it is focusing on research and development. Nevatia ...

Pfizer’s promising research on a treatment for a dangerous cancer-related condition is also helping prove out the value of wearables in clinical trials. In September, the pharma giant reported ...